RxSight, Inc. Form 10-Q Summary
Business context and reporting period
RxSight is a commercial-stage medical technology company that develops, manufactures and sells the Light Adjustable Lens (LAL) and Light Delivery Device (LDD) system for customized vision correction after cataract surgery. The report covers the unaudited quarter ended March 31, 2023, compared with the quarter ended March 31, 2022. Products are primarily sold in the United States, with regulatory approvals in additional international markets.
- LDD installed base reached 456 units at March 31, 2023, versus 246 at March 31, 2022.
- Quarterly LDD sales increased to 56 from 40.
- Quarterly LAL implants increased to 10,523 from 4,166; cumulative implants exceeded 52,000.
Financial performance and key metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Sales | $17.5 million | $8.9 million | Up 95.6% |
| Gross profit | $10.4 million | $3.8 million | Up 175.6% |
| Gross margin | 59.3% | 42.6% | Up 16.7 percentage points |
| SG&A expense | $16.3 million | $13.6 million | Up 19.3% |
| R&D expense | $7.2 million | $6.7 million | Up 7.3% |
| Loss from operations | $(13.1) million | $(16.6) million | Improved $3.5 million |
| Net loss | $(13.2) million | $(17.6) million | Improved $4.4 million |
| Basic and diluted loss per share | $(0.42) | $(0.64) | Improved |
| Operating cash flow | $(17.8) million | $(15.0) million | Higher use of $2.8 million |
- Revenue growth was driven primarily by 6,357 additional LAL implants and 16 additional LDD sales.
- Gross-margin expansion reflected higher volume, operating leverage and favorable product mix.
- SG&A increased primarily from expanded sales and marketing headcount, stock-based compensation and travel. R&D increased primarily from higher personnel and clinical-study costs.
- Interest expense increased to $1.5 million from $1.1 million, while interest and other income increased to $1.4 million from $0.05 million due largely to higher yields on short-term investments.
- Stock-based compensation was $3.3 million, compared with $2.6 million.
Balance sheet, cash flow, debt and liquidity
- Cash and cash equivalents were $11.0 million at March 31, 2023, compared with $11.8 million at December 31, 2022.
- Short-term investments were $142.9 million, compared with $94.0 million; cash, cash equivalents and short-term investments totaled $153.9 million versus $105.8 million at year-end 2022.
- Total assets were $202.5 million and total liabilities were $57.5 million.
- Inventory increased to $18.1 million from $14.8 million, while accounts receivable increased to $12.7 million from $11.0 million.
- Net cash used in investing activities was $48.4 million, primarily from net purchases of short-term investments and $0.7 million of capital expenditures.
- Net cash provided by financing activities was $65.3 million, including $53.6 million of net proceeds from a public offering, $10.9 million from ATM sales and $0.8 million from stock-option exercises.
- The term loan had a carrying value of $40.3 million and matures February 1, 2027. The facility bears interest at the greater of 9.25% or one-month Term SOFR plus 9.09%, subject to a 5% default-rate increase. The company was in compliance with its covenants.
- The company states that existing cash, cash equivalents and short-term investments are expected to fund operations and capital expenditures for at least 12 months from the filing date.
Material changes versus the prior comparable period
- Sales nearly doubled, led by substantially higher LAL utilization and continued expansion of the LDD installed base.
- Gross margin improved materially from 42.6% to 59.3% as volume increased and product mix improved.
- Operating and net losses narrowed, but the company remained loss-making and generated negative operating cash flow.
- Operating cash use worsened despite the lower net loss, reflecting increased inventory and accounts receivable investments and changes in accrued liabilities.
- The company materially strengthened liquidity through the February public offering and additional ATM issuance, increasing outstanding shares from 28.3 million at December 31, 2022 to 34.0 million at March 31, 2023.
Guidance, outlook, risks and unusual items
- Management expects continued net losses and negative operating cash flow as it expands sales and marketing, research and development, clinical activities and public-company infrastructure.
- Management does not currently anticipate needing additional capital or debt to reach operating profitability, but reserves the ability to access the ATM facility or pursue equity, debt, collaboration or other financing if liquidity needs require it.
- The lower-cost LDD received FDA approval on January 31, 2023, but market introduction was deferred until the second half of 2023. Producing both the existing and lower-cost LDDs is expected to pressure gross margin.
- Supply-chain constraints, inflation, higher interest rates, limited component availability and reliance on single- or sole-source suppliers could impair production or increase costs.
- Key business risks include limited operating history, continued losses, competition from larger medical-device companies, physician and patient adoption, reimbursement uncertainty, regulatory compliance, clinical-study outcomes, intellectual-property protection, product liability and cybersecurity or data-privacy incidents.
- The company has no material legal proceedings for which a loss is considered probable and reasonably estimable. It maintains a $0.3 million standby letter of credit related to an operating lease.
- Disclosure controls and procedures were concluded to be effective at March 31, 2023, and no material changes to internal control over financial reporting were reported during the quarter.
Important facts for investors to verify
- Whether rapid LAL utilization growth and the 456-unit LDD installed base continue to support revenue growth.
- Whether gross margin remains near the Q1 level after introduction of the lower-cost LDD and continued production of two LDD versions.
- The pace of operating cash consumption relative to the $153.9 million liquidity balance and the timing of potential profitability.
- Compliance with the term-loan financial covenant and the availability of up to $20.0 million of additional borrowing subject to contractual conditions and sales milestones.
- Potential dilution from the ATM facility, equity compensation and other future capital raises.
- Supply availability, component costs, regulatory compliance and the timing of the lower-cost LDD launch.
- Durability of reimbursement, physician adoption and patient demand for premium LAL procedures.